Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea
MOVIE-TRACE-WA
2 other identifiers
observational
992
1 country
1
Brief Summary
This study has three primary objectives to address the public health challenges of the Mpox outbreak in Guinea, West Africa. Objective 1 (MOVIE-West Africa) focuses on understanding the kinetics of Monkeypox virus (MPXV) elimination from the human body in Mpox cases. Objective 2 (TRACE-West Africa) aims to determine the MPXV transmission dynamics between Mpox cases and their contacts. Objective 3 (VE-West Africa) examines the vaccine effectiveness of the MVA-BN vaccine in protection against MPXV infection and Mpox disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 10, 2026
CompletedFirst Posted
Study publicly available on registry
April 16, 2026
CompletedStudy Start
First participant enrolled
April 16, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2027
April 16, 2026
April 1, 2026
11 months
April 10, 2026
April 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Viral clearance in oropharyngeal swabs
Time to viral clearance in oropharyngeal swabs (number of days from onset of symptoms to first negative PCR result).
From day 1 to day 56
Secondary attack rate of infection
Estimation of Secondary Attack Rate of infection (SAR-i), the proportion of contacts who become infected (PCR positive), regardless of exhibiting symptoms.
From day 1 to day 14
Secondary attack rate of disease
Estimation of Secondary attack rate of disease (SAR-d), the proportion of contacts who become infected (PCR positive) and develop symptoms.
From day 1 to day 28
Secondary Outcomes (4)
Viral clearance in skin lesions
From day 1 to day 56
Viral clearance in urine
From day 1 to day 56
Risk factors of transmission
From day 1 to day 14
Immunological assessments
From day 1 to day 56
Study Arms (3)
MOVIE
Confirmed Mpox cases
TRACE
Contacts of a MOVIE case
VE
Confirmed Mpox cases and their contacts
Eligibility Criteria
All individuals regardless of age or sex, who either have confirmed MPXV infection or have close contacts with a confirmed Mpox case.
You may qualify if:
- MOVIE-West Africa
- Individuals of any sex and age.
- Confirmed Mpox cases who tested positive for MPXV by PCR.
- Symptom onset within the 10 days prior to the baseline assessment.
- Willingness and ability to comply with study procedures and attend scheduled follow-up visits for up to two months.
- Availability for follow-up throughout the study period.
- Provision of written informed consent by the participant, or consent by a legally authorized representative for minors or individuals unable to provide it themselves.
- Assent obtained from children aged 12 to 17 years.
- For individuals who cannot read or write, witnessed consent will be obtained.
- TRACE-West Africa
- Individuals who have had close physical contact with a PCR-confirmed Mpox case within 14 days from the onset of symptoms in the index case.
- Close physical contact is defined as being within 2 meters of an infected person-particularly in enclosed spaces-for at least 5 minutes (based on CDC's 2-meter rule for droplet transmission).
- Willingness and ability to comply with the study protocol and attend scheduled follow-up assessments.
- Provision of written informed consent by the participant, or consent by a legally authorized representative for individuals unable to provide it themselves.
- Assent obtained from children aged 12 to 17 years.
- +9 more criteria
You may not qualify if:
- (1) MOVIE-West Africa
- Cases of severe Mpox requiring hospitalization.
- Individuals with a confirmed alternative diagnosis explaining their illness.
- (3) VE-West Africa
- Cases of severe Mpox requiring hospitalization.
- Individuals with a confirmed alternative diagnosis explaining their illness.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- London School of Hygiene and Tropical Medicinelead
- University of Glasgowcollaborator
- Centre National de Formation et de Recherche en Sante Ruralecollaborator
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Cienciacollaborator
- Agence Nationale de Sécurité Sanitaire de Guinée (ANSS)collaborator
- Institut National de la Santé Publique de Guinée (INSP)collaborator
Study Sites (1)
Centre National de Formation et de Recherche en Sante Rurale de Maferinyah
Conakry, Guinea
Related Publications (3)
Suner C, Ubals M, Tarin-Vicente EJ, Mendoza A, Alemany A, Hernandez-Rodriguez A, Casan C, Descalzo V, Ouchi D, Marc A, Rivero A, Coll P, Oller X, Miguel Cabrera J, Vall-Mayans M, Dolores Folgueira M, Angeles Melendez M, Agud-Dios M, Gil-Cruz E, Paris de Leon A, Ramirez Marinero A, Buhiichyk V, Galvan-Casas C, Paredes R, Prat N, Sala Farre MR, Bonet-Simo JM, Farre M, Ortiz-Romero PL, Clotet B, Garcia-Patos V, Casabona J, Guedj J, Cardona PJ, Blanco I; Movie Group; Marks M, Mitja O. Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain. Lancet Infect Dis. 2023 Apr;23(4):445-453. doi: 10.1016/S1473-3099(22)00794-0. Epub 2022 Dec 12.
PMID: 36521505BACKGROUNDTarin-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suner C, Anton A, Arando M, Arroyo-Andres J, Calderon-Lozano L, Casan C, Cabrera JM, Coll P, Descalzo V, Folgueira MD, Garcia-Perez JN, Gil-Cruz E, Gonzalez-Rodriguez B, Gutierrez-Collar C, Hernandez-Rodriguez A, Lopez-Roa P, de Los Angeles Melendez M, Montero-Menarguez J, Munoz-Gallego I, Palencia-Perez SI, Paredes R, Perez-Rivilla A, Pinana M, Prat N, Ramirez A, Rivero A, Rubio-Muniz CA, Vall M, Acosta-Velasquez KS, Wang A, Galvan-Casas C, Marks M, Ortiz-Romero PL, Mitja O. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022 Aug 27;400(10353):661-669. doi: 10.1016/S0140-6736(22)01436-2. Epub 2022 Aug 8.
PMID: 35952705BACKGROUNDMitja O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, Orkin CM. Monkeypox. Lancet. 2023 Jan 7;401(10370):60-74. doi: 10.1016/S0140-6736(22)02075-X. Epub 2022 Nov 17.
PMID: 36403582BACKGROUND
Biospecimen
blood, lesion swab, oropharyngeal swab, urine, vaginal swab, rectal swab
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Edward M Choi, PhD
London School of Hygiene and Tropical Medicine
- STUDY CHAIR
Michael E Marks, PhD
London School of Hygiene and Tropical Medicine
- STUDY CHAIR
Oriol Mitjà, PhD
Fundación FLS de lucha contra el sida las enfermedades infecciosas y la promoción de la salud y la ciencia, Spain
- PRINCIPAL INVESTIGATOR
Deborah Watson-Jones, PhD
London School of Hygiene and Tropical Medicine
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 56 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
April 10, 2026
First Posted
April 16, 2026
Study Start
April 16, 2026
Primary Completion (Estimated)
February 28, 2027
Study Completion (Estimated)
August 1, 2027
Last Updated
April 16, 2026
Record last verified: 2026-04